Catalent

Youtube Subscribe

Open: 37.0 Close: 37.44 Change: 0.44

Stop reading the whole internet to decide if you want to invest in Catalent Stock.

This document will help you to evaluate Catalent without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Catalent are: Catalent, stock, CTLT, delay, drug, year, cut, and the …

Concept Map

Semantic Network

Stock Summary

Catalent, Inc. develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for.

Today's Summary

Contract drug manufacturer Catalent (CTLT) delayed its quarterly results for the third time. The company said it expects to cut its full-year outlook. The contract drug manufacturer saw analysts get notably less bullish on its future.

Today's News

Catalent stock reverses to a near 6% loss after NYSE notice of noncompliance with listing standards. Catalent still struggling to get earnings over the finish line. Catalent (CTLT) jumped 14% to reverse losses despite guidance cut despite Q3 FY23 report delay and lower guidance. Bloom Energy experienced a notable 5.1% increase in its stock price after JPMorgan upgraded rating. Catalent shares jumped after the contract drug maker said customer supplies are strong and its getting significant new business. The contract drug manufacturer saw analysts get notably less bullish on its future. Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that hurt investor confidence in the contract drug manufacturer. Tyson Foods dropped 15.9% on a surprise second-quarter loss. Contract drug manufacturer Catalent (ticker: CTLT) delivered more bad news on Friday, but investors shrugged it off, securing the stock a top place in the S&P 500. Catalent said it now sees adjusted net income of $187-$228 million, down from $567- $648 million. The company continues to win significant new business. Contract drug manufacturer Catalent Inc (CTLT) delayed its quarterly results for the third time. The company said it expects to cut its full-year outlook. Shares dropped more than 25% on Monday. Catalent (CTLT) stock surges despite second earnings delay this month. This comes amid Catalent delaying its fiscal Q3 earnings release twice this month, initially posing severe concerns about CTLT stock. Catalent expects to earn between $725 million and $750 million this fiscal year. Catalent Pharma Solutions is Morrisville, NC is hiring an Operations Technician for the Analytical group. Catalent produces more than 70 billion doses per year, and each one will be used by someone who is counting on us. Catalent delayed its third quarter fiscal year 2023 financials for a third time and instead provided a business update Friday. Catalent highlighted the scaling up of a cost-reduction plan aimed at doubling its previous commitment of $75-85 million of annualized run-rate savings. The pharmaceutical company Catalent is cutting jobs in Bloomington as vaccine demand drops. Catalent Incs solvency score is38/100. The higher the solveny score, the more solvent the company is. Wall Street analysts forecast CTLT stock price to rise over the next year. Catalent stock price per share is $38.13 today (as of May 23, 2023) Catalent shares gained 0.1% to close at $32.14 on Thursday. The total value of Catalent (market capitalization) is $6.87B. Catalent issues profit warning, issues a profit warning. Zoetis down 6.5% since last Earnings Report: Can it Rebound?

Stock Profile

"Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey."

Keywords

How much time have you spent trying to decide whether investing in Catalent? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Catalent are: Catalent, stock, CTLT, delay, drug, year, cut, and the most common words in the summary are: catalent, stock, market, ctlt, best, news, price, . One of the sentences in the summary was: Contract drug manufacturer Catalent (CTLT) delayed its quarterly results for the third time. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #catalent #stock #market #ctlt #best #news #price.

Read more →

Youtube Subscribe

---